Guest post by Natalie Morrison, Senior Reporter at BioPharm Insight
BioPharm Insight’s (BPI) 1Q15 CRO report, compiled by analyst Peter Murphy, delves into trends and opportunities in the life sciences services sector.
The report notes oncology was the most trialed indication, totaling 20% of all human studies initiated in 1Q15. More notably, CNS trial launches rose from 12% to 15%, indicative of big pharma’s growing interest in the field.
Only two of the five most active CRO-sponsor relationships have multi-trial contracts, reflective of waning sponsor interest in strategic CRO partnerships.
In Asia Pacific, new trial launches dropped from 1,173 to 674 year-on-year. A particularly drastic decline in China was noted, potentially due to sluggish regulatory processes. In spite of this, Asia-Pac M&A remains strong for bigger CROs such as Clinipace, whose CEO earmarked Asia in its M&A strategy.